The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy: Prevalence and Prediction
Abstract
BACKGROUND: Interferon-alpha (IFN-alpha) plus ribavirin is used to treat hepatitis C virus (HCV) infection and is associated with a high rate of depression. Newer, pegylated preparations of IFN-alpha have a longer half-life, require once-per-week dosing, and may be associated with reduced neuropsychiatric burden. Limited data exist on depression during pegylated IFN-alpha therapy. METHOD: Depressive symptoms were assessed using the Zung Self-Rating Depression Scale (SDS) in 162 HCV-infected patients at baseline and after 4, 8, 12, and 24 weeks of treatment with pegylated IFN alpha-2b (PEG IFN) plus weight-based (N = 86) versus standard dose (N = 76) ribavirin. Data were collected from March 2001 to April 2003. RESULTS: Compared with baseline, mean SDS index scores were significantly increased by week 4 and remained elevated throughout the study. Thirty-nine percent of the sample experienced moderate to severe depressive symptoms (SDS index score > or = 60) at some point during PEG IFN/ribavirin therapy. Baseline depression scores significantly predicted severity of depressive symptoms during PEG IFN/ribavirin treatment (simple regression analysis: Y = 0.55X + 32.7, p < .0001). In addition, assignment to weight-based ribavirin treatment and history of depression were associated with increased likelihood of developing moderate to severe depressive symptoms (odds ratio [OR] = 2.7, 95% CI = 1.3 to 5.6, p < .01, and OR = 3.3, 95% CI = 1.3 to 8.1, p < .01, respectively). CONCLUSIONS: Development of moderate to severe depressive symptoms occurred frequently during PEG IFN/ribavirin treatment and was predicted by baseline depression scores and higher doses of ribavirin. History of major depressive disorder was also a significant predictive factor, but only through association with elevated baseline depression status. All of these factors can be evaluated and addressed to limit neuropsychiatric morbidity during HCV treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
A self-rating depression scale
ZUNG, W. W. K. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01720310065008 · Cited by 9,813
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Linear Mixed Models for Longitudinal Data
Verbeke, G. (1997) · Lecture Notes in Statistics · doi:10.1007/978-1-4612-2294-1_3 · Cited by 3,506
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., Kaslow, R. A., & Margolis, H. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908193410802 · Cited by 2,992
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Self-citation[Gastric adenocarcinoma and kidney transplantation].
Barrio, J., García-Bengoechea, M., Emparanza, J. I., & Arenas, J. I. (1998) · PubMed · Cited by 1,132
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
Self-citationMcHutchison, J. G., Manns, M., Patel, K., Poynard, T., Lindsay, K. L., Trepo, C., Dienstag, J., Lee, W. M., Mak, C., Garaud, J., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.35950 · Cited by 969
Alter, H. J., & Seeff, L. B. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9505 · Cited by 736
Neuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 422
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
Bodenheimer, H. C., Lindsay, K. L., Davis, G. L., Lewis, J. H., Thung, S. N., & Seeff, L. B. (1997) · Hepatology · doi:10.1002/hep.510260231 · Cited by 380
[Long-term treatment of depression].
Keller, M. B. (1994) · PubMed · Cited by 362
A concurrent validational study of the NCHS General Well-Being schedule.: (409022004-001)
Fazio, A. F. (1977) · PsycEXTRA Dataset · doi:10.1037/e409022004-001 · Cited by 326
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Gulati, M., Thornton, A. J., Schultz, R. L., Valentine, A. D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001119 · Cited by 313
Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus
Bonaccorso, S., Marino, V., Biondi, M., Grimaldi, F., Ippoliti, F., & Maes, M. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(02)00264-1 · Cited by 284
Long-term treatment of depression.
Kupfer, D. J. (1991) · PubMed · Cited by 272
INTERFERONS AS MEDIATORS OF PSYCHIATRIC MORBIDITY
Mcdonald, E. M., Mann, A. H., & Thomas, H. C. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91319-5 · Cited by 247
Psychiatric Symptoms in Patients With Chronic Hepatitis C Receiving Interferon Alfa-2b Therapy
Kraus, M. R., Schafer, A., Faller, H., Csef, H., & Scheurlen, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0614 · Cited by 245
A Computer-Administered Telephone Interview to Identify Mental Disorders
Kobak, K. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550110043034 · Cited by 238
Bernstein, D., Kleinman, L., Barker, C. M., Revicki, D. A., & Green, J. (2002) · Hepatology · doi:10.1053/jhep.2002.31311 · Cited by 231
Telephone assessment of depression severity
Simon, G. E., Revicki, D., & VonKorff, M. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90035-z · Cited by 220
Dieperink, E., Ho, S. B., Thuras, P., & Willenbring, M. L. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.2.104 · Cited by 218
Interferon alpha (IFNα) and psychiatric syndromes
Schaefer, M., Engelbrechta, M. A., Gut, O., Fiebich, B. L., Bauer, J., Schmidt, F., Grunze, H., & Lieb, K. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00324-4 · Cited by 202
Trask, P. C., Esper, P., Riba, M., & Redman, B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2316 · Cited by 191
A Descriptive Analysis of Minor Depression
Rapaport, M. H., Judd, L. L., Schettler, P. J., Yonkers, K. A., Thase, M. E., Kupfer, D. J., Frank, E., Plewes, J. M., Tollefson, G. D., & Rush, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.637 · Cited by 178
Schaefer, M., Schwaiger, M., Garkisch, A. S., Pich, M., Hinzpeter, A., Uebelhack, R., Heinz, A., van Boemmel, F., & Berg, T. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.01.020 · Cited by 175
Paroxetine for the treatment of interferon‐α‐induced depression in chronic hepatitis C
Kraus, M. R., Schäfer, A., Faller, H., Csef, H., & Scheurlen, M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01265.x · Cited by 170
Capuron, L., & Ravaud, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401716 · Cited by 169
Self-citationTreatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders
Pariante, C. M., Orrù, M. G., Baita, A., Farci, M. G., & Carpiniello, B. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04793-x · Cited by 165
A concurrent validational study of the NCHS General Well-Being Schedule.
Fazio, A. F. (1977) · PubMed · Cited by 159
Effect of Interferon-α Treatment of Chronic Hepatitis C on Health-Related Quality of Life
Hunt, C. M., Dominitz, J. A., Phillips‐Bute, B. G., Waters, B., Blasi, U., & Williams, D. M. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018852309885 · Cited by 141
Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00239-6 · Cited by 140
Depression From Interferon Therapy in Patients With Hepatitis C
Miyaoka, H., Otsubo, T., Kamijima, K., Ishii, M., ONUKI, M., & Mitamura, K. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1120 · Cited by 135
Fatigue, depression and chronic hepatitis C infection
Wessely, S. C., & Pariante, C. M. (2002) · Psychological Medicine · doi:10.1017/s0033291701004615 · Cited by 121
Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center
Lee, D. H., Jamal, H., Regenstein, F., & Perrillo, R. P. (1997) · Digestive Diseases and Sciences · doi:10.1023/a:1018818012378 · Cited by 104
Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C
Fontana, R. J., Moyer, C. A., Sonnad, S. S., Lok, A. S.-F., Sneed-Pee, N., Walsh, J. J., Klein, S., & Webster, S. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03473.x · Cited by 102
A Brief Depression Scale for Use in the Medically Ill
Koenig, H. G., Cohen, H. J., Blazer, D. G., Meador, K. G., & Westlund, R. E. (1992) · The International Journal of Psychiatry in Medicine · doi:10.2190/m1f5-f40p-c4kd-ypa3 · Cited by 99
Malaguarnera, M., Fazio, I. D., Restuccia, S., Pistone, G., Ferlito, L., & Rampello, L. (1998) · Neuropsychobiology · doi:10.1159/000026485 · Cited by 95
Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients
Gohier, B., Goëb, J.-L., Rannou-Dubas, K., Fouchard, I., Calès, P., & Garré, J.-B. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029904 · Cited by 87
Singh, N., Gayowski, T., Wagener, M. M., & Marino, I. R. (1997) · Clinical Transplantation · doi:10.1111/j.1399-0012.1997.tb00842.x · Cited by 82
Pretreatment symptoms and dosing regimen predict side‐effects of interferon therapy for hepatitis C
Cotler, Wartelle, Larson, Gretch, Jensen, & Jr, C. (2000) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2000.00215.x · Cited by 76
Kraus, M. R., Schäfer, A., Csef, H., Faller, H., Mörk, H., & Scheurlen, M. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1011973823032 · Cited by 73
Assessment of Depression in Patients with Chronic Viral Hepatitis: Effect of Interferon Treatment
Koskinas, J. S., Merkouraki, P., Manesis, E. K., & Hadziyannis, S. (2002) · Digestive Diseases · doi:10.1159/000067682 · Cited by 55
Emotional Distress During Interferon-α-2B and Ribavirin Treatment of Chronic Hepatitis C
Fontana, R. J., Schwartz, S. M., Gebremariam, A., Lok, A. S.-F., & Moyer, C. A. (2002) · Psychosomatics · doi:10.1176/appi.psy.43.5.378 · Cited by 45
[Depression during interferon therapy in chronic hepatitis C patients--a prospective study].
Otsubo, T., Miyaoka, H., Kamijima, K., ONUKI, M., Ishii, M., & Mitamura, K. (1997) · PubMed · Cited by 35
333 Citalopram for prevention of interferon-alpha associated depression in psychiatric risk patients
SCHAEFER, M., Schwaiger, M., & Berg, T. (2003) · Hepatology · doi:10.1016/s0270-9139(03)80376-2 · Cited by 4
Cited by
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“…interferon-a (IFN-a) has also been found to induce depressive symptoms, with as many as 30–50% of IFN-atreated patients meeting the symptom criteria for major depression (according to the Diagnostic and Statistical Manual IV) depending on the dose (Musselman et al, 2001; Raison et al, 2005a, b).”
BackgroundInfluentialSelf-citationDepression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., Starkstein, S., Weintraub, D., Poewe, W., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 683
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Self-citation
Metadata
- Authors
- Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-01-15
- Volume
- 66
- Issue
- 01
- Pages
- 41-48
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2018896573
- Cited by
- 299
- References
- 50
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.